Detalhe da pesquisa
1.
Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
Exp Parasitol
; 257: 108687, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114040
2.
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
J Antimicrob Chemother
; 78(7): 1723-1731, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37229566
3.
Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Molecules
; 25(17)2020 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887341
4.
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis.
Antimicrob Agents Chemother
; 63(9)2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31262757
5.
Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
Antimicrob Agents Chemother
; 62(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263075
6.
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.
Antimicrob Agents Chemother
; 62(10)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30082295
7.
Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.
Antimicrob Agents Chemother
; 62(5)2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29507073
8.
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Antimicrob Agents Chemother
; 61(8)2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28607026
9.
Drug permeation and barrier damage in Leishmania-infected mouse skin.
J Antimicrob Chemother
; 71(6): 1578-85, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26903275
10.
Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities.
RSC Med Chem
; 12(4): 472-482, 2021 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34041488
11.
Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis.
Pharmaceutics
; 13(4)2021 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33918099
12.
Characterization of a new Leishmania major strain for use in a controlled human infection model.
Nat Commun
; 12(1): 215, 2021 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33431825
13.
Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs.
Semin Immunopathol
; 42(3): 247-264, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32152715
14.
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis.
Int J Parasitol Drugs Drug Resist
; 11: 129-138, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922847
15.
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.
Int J Parasitol Drugs Drug Resist
; 11: 106-117, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320296
16.
A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis.
PLoS Negl Trop Dis
; 13(5): e0007373, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31120889
17.
Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis.
Int J Parasitol Drugs Drug Resist
; 8(2): 223-228, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29673889
18.
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
J Pharm Pharmacol
; 68(7): 862-72, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27230300